Floyd Malveaux, MD, PhD, Executive Director of the Merck Childhood Asthma Network, Inc, talks about his organization and its support of a federal action plan to reduce racial and ethnic disparities in childhood asthma care in a Pulmonary Reviews exclusive audiocast. [More]
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or death (with video). [More]
Margaret Rosenfeld, MD, MPH, from Seattle Children's Hospital, provides insight into her study on hypertonic saline in children with cystic fibrosis. [More]
Dr. Nancy Collop shares an insider's perspective on the 26th Annual Meeting of the Associated Professional Sleep Societies, LLC. [More]
Last month, Rocker et al highlighted discrepancies between the positive experiences of patients and family caregivers with the use of opioids for refractory dyspnea, and the reluctance of Canadian physicians to prescribe such therapy. This gap in clinical care is difficult to explain, particularly in the context of extensive exploration of the safety and efficacy of the therapy. [More]
David Cohn, MD, Professor of Medicine, Division of Infectious Diseases at the University of Colorado Health Sciences Center, Denver, provides insight into the significance of the International Standards for Tuberculosis Care. [More]
By Danielle Ramo, PhD—Marijuana use among young adult smokers is an increasingly prevalent problem, and clinicians who work with smokers need to find ways to incorporate multiple substance use into their patients’ treatment plans. [More]
(See video at the end of this post of Deborah Schrag, ME, MPH, from the Dana-Farber Cancer Institute, talking about the implications of the study.)
Adding bevacizumab to the standard chemotherapy regimen for non–small cell lung cancer (NSCLC)—an approach approved by the FDA in 2006—did not lead to significantly increased survival rates for patients older than 65 enrolled in Medicare, according to the results of a new study by researchers from Dana-Farber Cancer Institute, Boston, published in the April 18 JAMA.
In a previous trial, adding bevacizumab to the standard carboplatin-paclitaxel treatment for NSCLC improved survival in many patients with advanced disease, but not those in the 65 and older age range. Based on the new findings, the study authors recommended that bevacizumab not be automatically administered together with carboplatin-paclitaxel for older patients with NSCLC. They also suggested that physicians exercise caution in making treatment recommendations and use bevacizumab judiciously. [More]
Audiocast By Timothy R. Aksamit, MD
Earlier this year, the COPD Foundation expanded its Bronchiectasis Research Registry to include patients with nontuberculous Mycobacteria (NTM), an often misdiagnosed orphan disease that can cause severe lung infections that mimic tuberculosis when certain individuals are exposed to soil and water.
According to John W. Walsh, President of the COPD Foundation, “NTM lung disease is a devastating illness that is challenging to treat. For unknown reasons, a once productive individual struck with NTM is often left with permanent lung damage and recurring illness, including loss of hearing and vision.”
According to John W. Walsh, President of the COPD Foundation, “NTM lung disease is a devastating illness that is challenging to treat. For unknown reasons, a once productive individual struck with NTM is often left with permanent lung damage and recurring illness, including loss of hearing and vision.” [More]
From March 1, 2012 to December 1, 2012, anyone who completes the registration on this website will be automatically eligible to win an iPad! A winner will be chosen at random.
Winning an iPad is not the only benefit of registering at PulmonaryReviews.com. In addition, you will have full access to our Postgraduate Study Guide quizzes. The quizzes—on a full range of topics such as pleural disease, asthma, pneumonia, sleep medicine, and lung transplantation—are designed to assist pulmonologists in preparing for the board examinations.
Registration also gives you the opportunity to comment here on blog posts. And when you register, our Email Blasts will alert you to the website’s latest content—from news articles to audiocasts of experts discussing their research. [More]